Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16353272 | 0.97 | THRB (0.39) | THRBALDH1A1TSHR | |
| SCHEMBL7113288 | 0.97 | THRB (0.35) | THRBALDH1A1TSHR | |
| SCHEMBL45482 | 0.94 | THRB (0.36) | THRBALDH1A1TSHRTP53CYP3A4 | |
| SCHEMBL17460096 | 0.92 | THRB (0.35) | THRBALDH1A1TSHR | |
| SCHEMBL21291961 | 0.92 | THRB (0.35) | THRBALDH1A1TSHR | |
| SCHEMBL4396584 | 0.92 | THRB (0.35) | THRBALDH1A1TSHR | |
| SCHEMBL17460095 | 0.92 | THRB (0.35) | THRBALDH1A1TSHR | |
| SCHEMBL13616508 | 0.92 | THRB (0.35) | THRBALDH1A1TSHR | |
| SCHEMBL15856920 | 0.90 | THRB (0.32) | THRBTSHRMAPK1 | |
| SCHEMBL12191395 | 0.89 | THRB (0.34) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012027717-A2 | FLOURESCENCE LABELING REAGENTS AND USES THEREOF | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | ESPERION THERAPEUTICS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | GPR119, ECHS1, PNLIP | THRB 2773/4885ALDH1A1 2677/4885TSHR 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.